罗米地辛联合阿扎胞苷治疗不适合强化疗的高危急性髓系白血病耐受良好且具临床活性
ROMAZA试验在不适合强化疗的急性髓系白血病患者中确定罗米地辛联合阿扎胞苷的最大耐受剂量为罗米地辛12 mg/m2(第8、15天)联合阿扎胞苷75 mg/m2(7/28天周期)。
要点
- 联合方案最大耐受剂量:罗米地辛12 mg/m2第8、15天,阿扎胞苷75 mg/m2 7/28天周期。
- 最佳缓解:完全缓解/不完全完全缓解7例,部分缓解2例。
核心结论
- 罗米地辛联合阿扎胞苷在不适合强化疗的成人高危急性髓系白血病中耐受良好且具临床活性。
研究设计与样本
- ROMAZA试验,在急性髓系白血病患者中确定联合方案的最大耐受剂量,38例患者接受最大耐受剂量治疗。
主要发现
- 最佳缓解:完全缓解/不完全完全缓解7例,部分缓解2例。
- 相关下一代测序研究为治疗耐药提供了重要见解。
关键数值与推荐
- 最大耐受剂量:罗米地辛12 mg/m2第8、15天,阿扎胞苷75 mg/m2 7/28天周期。
临床怎么用
- 对于不适合强化疗的高危急性髓系白血病成人患者,可考虑罗米地辛联合阿扎胞苷治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Azacitidine (AZA) is important in the management of patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Romidepsin (ROM) is a histone deacetylase inhibitor which synergises with AZA in vitro. The ROMAZA trial established the maximum tolerated dose (MTD) of combined ROM/AZA therapy in patients with AML, as ROM 12 mg/m2 on Days 8 and 15, with AZA 75 mg/m2 administered for 7/28 day cycle. Nine of the 38 (23·7%) patients treated at the MTD were classified as responders by Cycle 6 (best response: complete remission [CR]/incomplete CR n = 7, partial response n = 2). Correlative next-generation sequencing studies demonstrated important insights into therapy resistance.
引用
- Loke J, Metzner M, Boucher R, et al. Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy. Br J Haematol. 2021. PMID: 34490623. doi:10.1111/bjh.17823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。